Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis

PHASE4RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 17, 2020

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2030

Conditions
Systemic SclerosisSystemic Scleroses, DiffuseSclerodermaScleroderma, DiffuseAutologous Stem Cell TransplantationCyclophosphamideMycophenolate MofetilTreatment Strategy
Interventions
PROCEDURE

Upfront autologous HSCT

"HSCT comprises the following consecutive steps:~1. Mobilisation~ * Infusions of CYC 2g/m2 on 1 day.~ * Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~ * Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~2. Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10\^6 CD34+ cells per kilogram body weight.~3. Conditioning~ * CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~ * Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~ Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~ I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~4. Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10\^6/kg."

Trial Locations (12)

Unknown

NOT_YET_RECRUITING

Gaetano Pini-CTO, Milan

RECRUITING

Ospedale San Raffaele, Milan

NOT_YET_RECRUITING

University Hospital Rome, Roma

RECRUITING

Amsterdam Rheumatology Centre, Amsterdam

RECRUITING

University Medical Centre Leiden, Leiden

RECRUITING

Radboudumc Nijmegen, Nijmegen

RECRUITING

University Medical Centre Utrecht, Utrecht

RECRUITING

Skåne University Hospital Lund, Lund

RECRUITING

Karolinska Institute/Karolinska University Hospital Solna, Stockholm

NOT_YET_RECRUITING

University Hospital Basel, Basel

NOT_YET_RECRUITING

Inselspital, Universitätsspital Bern, Bern

NOT_YET_RECRUITING

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Miltenyi Biotec, Inc.

INDUSTRY

lead

UMC Utrecht

OTHER

NCT04464434 - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis | Biotech Hunter | Biotech Hunter